# Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer

> **NCT07018063** · PHASE2 · NOT_YET_RECRUITING · sponsor: **zhoujing** · enrollment: 35 (estimated)

## Conditions studied

- Gastric (Cardia, Body) Cancer
- Stomach Adenocarcinoma
- Locally Advanced

## Interventions

- **DRUG:** nab-paclitaxel
- **DRUG:** oxaliplatin
- **DRUG:** S-1
- **DRUG:** sintilimab
- **PROCEDURE:** D2 Gastrectomy

## Key facts

- **NCT ID:** NCT07018063
- **Lead sponsor:** zhoujing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2027-12-30
- **Final completion:** 2030-06-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07018063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07018063, "Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07018063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*